BBR can reduce steatosis by increasing ATP-binding cassette transporter A1 (ABCA1) protein levels through PKCδ to reduce the phosphorylation of serine residues in ABCA1 (Liang and Wang, 2018). The gene discussed is ABCA1; the disease is steatosis.